Literature DB >> 17160378

[The effectiveness of the new fluoroquinolones against the normal bacterial flora of the conjunctiva].

M J Koss1, M Eder, M S Blumenkranz, V Klauss, C N Ta, H M de Kaspar.   

Abstract

BACKGROUND: Our aim was to determine the antibiotic susceptibility of the preoperative conjunctival bacterial flora against 25 commonly used antibiotics, especially the new fluoroquinolones levofloxacin, gatifloxacin, and moxifloxacin. PATIENTS AND METHODS: The Kirby-Bauer disk-diffusion technique was used to test for the in vitro antibiotic susceptibility of conjunctival bacterial strains isolated from 160 patients (median=74 years, mean=71 years) undergoing cataract surgery at the Department of Ophthalmology, Stanford University, CA, USA.
RESULTS: Among the 256 bacteria isolated, 201 (79%) were coagulase-negative staphylococci (CNS), 26 Staphylococcus aureus, 15 Streptococcus group D and 14 gram-negative rods. A total of 100 of these 256 strains (39%) were classified as multiresitant (resistant to>or=five antibiotics). The resistance rate (RR) of commonly used antibiotics for all CNS was: gatifloxacin=moxifloxacin<gentamycin=tobramycin=levofloxacin=neomycin<ciprofloxacin=ofloxacin<erythromycin. The RR for S. aureus and the gram-negative rods was low and insignificant in comparison to the other antibiotics tested. None of the Streptococcus group D were resistant to gatifloxacin, levofloxacin, or moxifloxacin, however, they were highly resistant (RR over 30%) to the other antibiotics. Some 50% of the bacteria were resistant to erythromycin.
CONCLUSION: Newer generation fluoroquinolones provide excellent efficacy against coagulase-negative staphylococci and Streptococcus group D despite a high number of multiresitant bacteria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17160378     DOI: 10.1007/s00347-006-1453-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  32 in total

1.  ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Preliminary report of principal results from a European multicenter study.

Authors:  Peter Barry; David V Seal; George Gettinby; Fiona Lees; Magnus Peterson; Crawford W Revie
Journal:  J Cataract Refract Surg       Date:  2006-03       Impact factor: 3.351

2.  Lomefloxacin is an effective treatment of experimental bacterial keratitis.

Authors:  R P Kowalski; E G Romanowski; K A Yates; Y J Gordon
Journal:  Cornea       Date:  2001-04       Impact factor: 2.651

3.  Preventing, diagnosing, and treating endophthalmitis.

Authors:  S Masket
Journal:  J Cataract Refract Surg       Date:  1998-06       Impact factor: 3.351

Review 4.  Mechanism of fluoroquinolone action.

Authors:  K Drlica
Journal:  Curr Opin Microbiol       Date:  1999-10       Impact factor: 7.934

5.  Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.

Authors:  M C García-Sáenz; A Arias-Puente; M J Fresnadillo-Martinez; C Carrasco-Font
Journal:  J Cataract Refract Surg       Date:  2001-12       Impact factor: 3.351

6.  Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis.

Authors:  M G Speaker; F A Milch; M K Shah; W Eisner; B N Kreiswirth
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

7.  Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.

Authors:  M H Goldstein; R P Kowalski; Y J Gordon
Journal:  Ophthalmology       Date:  1999-07       Impact factor: 12.079

8.  Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.

Authors:  Rookaya Mather; Lisa M Karenchak; Eric G Romanowski; Regis P Kowalski
Journal:  Am J Ophthalmol       Date:  2002-04       Impact factor: 5.258

9.  [Coagulase-negative staphylococci in normal and chronically inflamed conjunctiva].

Authors:  T Grasbon; H Miño de Kaspar; V Klauss
Journal:  Ophthalmologe       Date:  1995-12       Impact factor: 1.059

10.  [Endophthalmitis. Importance of microbiologic studies for therapy and prognosis].

Authors:  H Miño de Kaspar; M Kollmann; V Klauss
Journal:  Ophthalmologe       Date:  1993-12       Impact factor: 1.059

View more
  4 in total

1.  [Introduction to the topic: bacterial keratitis. From the proven to the new].

Authors:  U Pleyer; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2007-01       Impact factor: 1.059

Review 2.  [Therapy and prognosis of bacterial keratitis].

Authors:  W Behrens-Baumann; U Pleyer
Journal:  Ophthalmologe       Date:  2007-01       Impact factor: 1.059

3.  The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.

Authors:  Jose Benitez-Del-Castillo; Yves Verboven; David Stroman; Laurent Kodjikian
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].

Authors:  M Kernt; C Hirneiss; A S Neubauer; R G Liegl; K H Eibl; A Wolf; H de Kaspar; M W Ulbig; A Kampik
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.